9 clinical trials found.
-
A Phase 2 Trial of the Combination of Polatuzumab Vedotin Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma
The purpose of the study is to evaluate the activity of a novel triplet combination of rituximab and hyaluronidase human, polatuzumab vedotin, and venetoclax for ... -
A PHASE Ib STUDY EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF VENETOCLAX IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB (R) AND CYCLOPHOSPHAMIDE DOXORUBICIN PREDNISONE (CHP) IN PATIENTS WITH UNTREATED BCL-2 IMMUNOHISTOCHEMISTRY (IHC) POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA
The purpose of this study is to test two different dosing schedules of an experimental drug called venetoclax. Venetoclax works by blocking a protein in ... -
A PHASE 1 OPEN-LABEL DOSE FINDING STUDY OF CC-95251 A MONOCLONAL ANTIBODY DIRECTED AGAINST SIRPa ALONE AND IN COMBINATION WITH CETUXIMAB OR RITUXIMAB IN SUBJECTS WITH ADVANCED SOLID AND HEMATOLOGIC CANCERS
The purpose of the study is to look at how your body tolerates CC-95251 and safety of the CC-95251 when administered intravenously (IV) as single ... -
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine Rituximab High Dose Cytarabine and Acalabrutinib (BR/CR-A) and 3.) Bendamustine Rituximab and Acalabrutinib (BR-A) in Patients = 70 years old with Untreated Mantle Cell Lymphoma
The purpose of the study is to determine the efficacy and tolerability of bendamustine (B), rituximab (R) and high dose cytarabine (C) [(BR/CR] versus ... -
A Phase 1-2 First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Lymphomas.
The study is being done to look at: • The possible side effects, safety and tolerability of CX-2029 • The highest dose of CX-2029 that can be ... -
A Phase 1 Study of TJ011133 Administered Alone or in Combination with Pembrolizumab or Rituximab in Subjects with Relapsed/Refractory Advanced Solid Tumors and Lymphoma
The purpose of this study is to test the safety of a study drug called TJ011133 alone, and to test the safety of TJ011133 in ... -
A PHASE IB-II STUDY OF HIGH-DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE BORTEZOMIB ABATACEPT AND SHORT-DURATION TACROLIMUS FOR THE PREVENTION OF GRAFT-VERSUS-HOST DISEASE (GVHD) FOLLOWING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
The purpose of the study is to determine the safety and efficacy of cyclophosphamide, abatacept, and short-duration tacrolimus for GvHD prophylaxis following haploidentical hematopoietic stem ... -
AN OPEN-LABEL MULTICENTER PHASE l/1B TRIAL EVALUATING THE SAFETY ANDPHARMACOKINETICS OF ESCALATING DOSES OF BTCT4465A AS A SINGLE AGENT ANDCOMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORYB-CELL NON-HODGKIN S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA
If you have been diagnosed with non-Hodgkin s lymphoma (NHL) or chronic lymphocytic leukemia (CLL) that relapsed after previous treatment(s), did not respond to ... -
A Phase 1 Study with an Expansion Cohort/Randomized Phase II Study of the Combination of Ipilimumab Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
If you have been newly diagnosed with relapsed/refractory Hodgkin lymphoma and are exploring treatment options, you may qualify for a clinical trial studying effect ...
